Abstract | BACKGROUND:
Triptans are a family of selective serotonin (5-HT1B/1D) receptor agonists that are widely used to treat acute migraine attacks. Their efficacy is limited by side effects and the gastrointestinal manifestations of migraine. AIM: METHODS: Patients were selected from those who presented to the emergency room with a diagnosed migraine attack and who had not previously taken any analgesics. They were randomized into 2 groups: treatment with a single 1g IV dose of propacetamol or with a single oral dose of 5mg rizatriptan. Their Visual Analogue Scale (VAS) pain scores were assessed before and at 30, 60, and 120min after treatment. RESULTS: The patients who received the propacetamol had significantly improved VAS scores at 60min compared to the rizatriptan group. There were no significant differences in VAS scores at 30 or 120min post-treatment. CONCLUSION:
|
Authors | Aiwu Zhang, Tao Jiang, Yifeng Luo, Zhenyang Zheng, Xiaolei Shi, Zijian Xiao, Yannan Fang |
Journal | European journal of internal medicine
(Eur J Intern Med)
Vol. 25
Issue 7
Pg. 629-32
(Sep 2014)
ISSN: 1879-0828 [Electronic] Netherlands |
PMID | 25002083
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014. Published by Elsevier B.V. |
Chemical References |
- Analgesics
- Prodrugs
- Acetaminophen
- propacetamol
|
Topics |
- Acetaminophen
(administration & dosage, analogs & derivatives)
- Acute Disease
- Adult
- Analgesics
(administration & dosage)
- Dose-Response Relationship, Drug
- Female
- Follow-Up Studies
- Humans
- Infusions, Intravenous
- Male
- Migraine Disorders
(drug therapy)
- Prodrugs
- Retrospective Studies
- Treatment Outcome
|